Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer by Janos L. Tanyi, Cheryl L.-L. Chiang, Johanna Chiffelle, Anne-Christine Thierry, Petra Baumgartener, Florian Huber, Christine Goepfert, David Tarussio, Stephanie Tissot, Drew A. Torigian, Harvey L. Nisenbaum, Brian J. Stevenson, Hajer Fritah Guiren, Ritaparna Ahmed, Anne-Laure Huguenin-Bergenat, Emese Zsiros, Michal Bassani-Sternberg, Rosemarie Mick, Daniel J. Powell, George Coukos, Alexandre Harari, Lana E. Kandalaft

“…We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. …”
Get full text

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database by Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, Daniel George

“…The most common 1 L treatment was sunitinib (n = 849), followed by pazopanib (n = 631), temsirolimus (n = 157) and bevacizumab (n = 154). Patient characteristics and comorbidities, including age, diabetes and congestive heart failure, were independent predictors of 1 L mRCC treatment choice. …”
Get full text

Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment by Dorcas A. Annan, Nako Maishi, Tomoyoshi Soga, Randa Dawood, Cong Li, Hiroshi Kikuchi, Takayuki Hojo, Masahiro Morimoto, Tetsuya Kitamura, Mohammad Towfik Alam, Kazuyuki Minowa, Nobuo Shinohara, Jin-Min Nam, Yasuhiro Hida, Kyoko Hida

“…However, matured blood vessel number increased after acetazolamide treatment, similar to bevacizumab treatment. Additionally, acetazolamide-treated mice showed decreased lung metastasis. …”
Get full text

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced <i>EGFR</i>-Mutated,... by Jianchao Xue, Bowen Li, Yadong Wang, Zhicheng Huang, Xinyu Liu, Chao Guo, Zhibo Zheng, Naixin Liang, Xiuning Le, Shanqing Li

“…Considering safety, ramucirumab and bevacizumab may be the ideal additions to TKIs (systematic review registration: PROSPERO CRD42022350474).…”
Get full text

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica by Beatriz Carvalho, Paulo Freitas-Costa, João Pinheiro-Costa, Manuel Falcão, Ângela Carneiro, Fernando Falcão-Reis

“…Os objetivos deste estudo são avaliar os resultados a longo prazo do tratamento antiangiogénico, com ranibizumab e/ou bevacizumab, na neovascularização coroideia associada à miopia patológica e caraterizar os fatores preditivos dos resultados funcionais e anatómicos obtidos. …”
Get full text

Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins by Morgane Daurat, Corentin Gauthier, Corentin Gauthier, Khaled El Cheikh, Lamiaa M. A. Ali, Lamiaa M. A. Ali, Elodie Morère, Elodie Morère, Nadir Bettache, Magali Gary-Bobo, Alain Morère, Marcel Garcia, Marie Maynadier, Ilaria Basile

“…The improvement of the therapeutic potential by AMFA engineering was investigated using two antibodies directed against soluble antigens: infliximab (IFX), directed against tumor necrosis factor α (TNF-α), and bevacizumab (BVZ), directed against the vascular endothelial growth factor (VEGF). …”
Get full text

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy by Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Cyrla Hoffert, Archana Srivastava, Anna Schab, Thierry Alcindor, Adrian Langleben, Lucas Sideris, Mahmoud Abdelsalam, Mustapha Tehfe, Felix Couture, Gerald Batist, Petr Kavan

“…In this clinical study (NCT01949194), we evaluated the safety and efficacy of single-agent regorafenib as a second-line therapy for mCRC patients who received it after failing first-line therapy with an oxaliplatin or irinotecan regimen with or without bevacizumab. Using various omics approaches, we also investigated putative biomarkers of response and resistance to regorafenib in metastatic lesions and blood samples in the same cohort. …”
Get full text

Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan by Shin-ichi Yamada, Hiroshi Kurita, Akira Tanaka, Masaru Miyata, Yoshinari Morimoto, Akira Yamaguchi, Souichi Yanamoto, Hiromasa Yoshikawa, Yutaka Imai

“…In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. …”
Get full text

Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation by Jordi Yang Zhou, Jordi Yang Zhou, Dominik Eder, Florian Weber, Philipp Heumann, Katharina Kronenberg, Jens M. Werner, Edward K. Geissler, Hans J. Schlitt, James A. Hutchinson, Florian Bitterer

“…BackgroundThe approval of Atezolizumab / Bevacizumab therapy (Atezo/Bev) in 2020 opened up a promising new treatment option for patients with end-stage hepatocellular carcinoma (HCC). …”
Get full text

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study by Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu Roulleaux Dugage, Stéphane Oudard, Constance Thibault

“…All patients received first-line platinum chemotherapy ± bevacizumab, with a median time to progression of 7.27 (95% CI, 7–100 months and an objective response rate (ORR) of 39% (95% CI, 26–52%). …”
Get full text

Successful management of malignant colovesical fistula using covered colonic self-expanding metallic stent: a case report by Goro Takahashi, Akihisa Matsuda, Takeshi Yamada, Kay Uehara, Seiichi Shinji, Yasuyuki Yokoyama, Takuma Iwai, Kohki Takeda, Sho Kuriyama, Toshimitsu Miyasaka, Shintaro Kanaka, Tai Terayachi, Tetsuya Okino, Hiroshi Yoshida

“…Case presentation A 75-year-old man undergoing infusional 5-fluorouracil and irinotecan chemotherapy plus bevacizumab for recurrent peritoneal dissemination of rectal cancer was admitted to our hospital because of fecaluria with a high-grade fever. …”
Get full text

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures by Joshua Alcaniz, Lars Winkler, Mathias Dahlmann, Michael Becker, Andrea Orthmann, Johannes Haybaeck, Johannes Haybaeck, Johannes Haybaeck, Stefanie Krassnig, Christina Skofler, Tobias Kratzsch, Susanne A. Kuhn, Andreas Jödicke, Michael Linnebacher, Iduna Fichtner, Wolfgang Walther, Wolfgang Walther, Wolfgang Walther, Jens Hoffmann

“…Best treatment responses were observed for standard of care temozolomide, irinotecan and bevacizumab. Matching orthotopic models frequently show reduced sensitivity, as the blood-brain barrier limits crossing of the drugs to the GBM. …”
Get full text

Spinal ependymoma in adults: from molecular advances to new treatment perspectives by Giulia Cerretti, Federico Pessina, Federico Pessina, Enrico Franceschi, Valeria Barresi, Alessandro Salvalaggio, Alessandro Salvalaggio, Marta Padovan, Renzo Manara, Renzo Manara, Vincenzo Di Nunno, Beatrice Claudia Bono, Beatrice Claudia Bono, Giovanni Librizzi, Mario Caccese, Marta Scorsetti, Marta Maccari, Giuseppe Minniti, Giuseppe Minniti, Pierina Navarria, Giuseppe Lombardi

“…Other studies have explored the use of temozolomide, platinum compounds, etoposide, and bevacizumab, but standard treatment options have not yet been defined. …”
Get full text

The close interaction between hypoxia-related proteins and metastasis in pancarcinomas by Andrés López-Cortés, Lavanya Prathap, Esteban Ortiz-Prado, Nikolaos C. Kyriakidis, Ángela León Cáceres, Isaac Armendáriz-Castillo, Antonella Vera-Guapi, Verónica Yumiceba, Katherine Simbaña-Rivera, Gabriela Echeverría-Garcés, Jennyfer M. García-Cárdenas, Andy Pérez-Villa, Patricia Guevara-Ramírez, Andrea Abad-Sojos, Jhommara Bautista, Lourdes Puig San Andrés, Nelson Varela, Santiago Guerrero

“…Six of them were involved in advanced-stage clinical trials: aflibercept, bevacizumab, cetuximab, erlotinib, ipatasertib, and panitumumab.…”
Get full text

A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer by Dennis Poel, Elske C. Gootjes, Lotte Bakkerus, Wim Trypsteen, Henk Dekker, Hans J. van derVliet, Nicole C. T. vanGrieken, Cornelis Verhoef, Tineke E. Buffart, Henk M. W. Verheul

“…Methods Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5‐FU/LV with oxaliplatin ± bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. …”
Get full text

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study by Guang Cao, Xiaodong Wang, Hui Chen, Song Gao, Jianhai Guo, Peng Liu, Haifeng Xu, Liang Xu, Xu Zhu, Renjie Yang

“…Methods This study analyzed 47 patients treated with hepatic arterial infusion chemotherapy plus regorafenib after standard systemic oxaliplatin and/or irinotecan in combination with bevacizumab or cetuximab between Jan 2017 and Jun 2020. …”
Get full text

Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future by Neda Minaei, Roya Ramezankhani, Atena Tamimi, Abbas Piryaei, Ali Zarrabi, Amir Reza Aref, Ebrahim Mostafavi, Massoud Vosough

“…Combination of programmed cell death ligand-1 (PD-L1) antibody Atezolizumab and vascular endothelial growth factor (VEGF) antibody Bevacizumab has become the standard of care in the first-line therapy for untestable HCC, approved by regulatory agencies. …”
Get full text

MUTATIONAL STATUS OF ONCOGENE KRAS AND RISK OF VENOUS THROMBOSIS IN PATIENTS WITH METASTATIC COLORECTAL CANCER by EC Malafaia, P Doria, L Teixeira, G Pita, Y Zollinger, P Almeida

“…Although Ades, et al. (2015) found mutated KRAS as risk factor for VTE and remained significant despite adjustment for Khorana score and bevacizumab treatment, data are insufficient and conflicting. …”
Get full text

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation by Chao Ren, Zhigang Chen, Yuhong Li, Lei Wen, Xiaomeng Ji, William Pat Fong, Qiong Shao, Yanyu Cai, Binkui Li, Yunfei Yuan, Deshen Wang

“…The four CRLM patients received toripalimab or sintilimab plus chemotherapy (FOLFOX or FOLFIRI or XELOX) with or without bevacizumab after POLE EDM were detected. All four patients achieved a radiological partial response. …”
Get full text

P48 by S. Solodskikh, V. Bashmakov, T. Gorbacheva, A. Panevina, A. Maslov, A. Mikhailov, I. Moshurov, V. Popov

“…Target drugs (e.g. sunitinib, bevacizumab, α-interferon, sorafenib) are more preferable in RCC therapy. …”
Get full text